Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

Molecular Psychiatry
S Le HellardVidar M Steen

Abstract

Atypical antipsychotics are nowadays the most widely used drugs to treat schizophrenia and other psychosis. Unfortunately, some of them can cause major metabolic adverse effects, such as weight gain, dyslipidemia and type 2 diabetes. The underlying lipogenic mechanisms of the antipsychotic drugs are not known, but several studies have focused on a central effect in the hypothalamic control of appetite regulation and energy expenditure. In a functional convergent genomic approach we recently used a cellular model and demonstrated that orexigenic antipsychotics that induce weight gain activate the expression of lipid biosynthesis genes controlled by the sterol regulatory element-binding protein (SREBP) transcription factors. We therefore hypothesized that the major genes involved in the SREBP activation of fatty acids and cholesterol production (SREBF1, SREBF2, SCAP, INSIG1 and INSIG2) would be strong candidate genes for interindividual variation in drug-induced weight gain. We genotyped a total of 44 HapMap-selected tagging single nucleotide polymorphisms in a sample of 160 German patients with schizophrenia that had been monitored with respect to changes in body mass index during antipsychotic drug treatment. We found a strong ...Continue Reading

References

Mar 10, 1998·Molecular Psychiatry·T BrömelJ Hebebrand
Dec 9, 2000·Biochimica Et Biophysica Acta·P A EdwardsA Venkateswaran
Feb 4, 2003·The American Journal of Psychiatry·Jean-Pierre LindenmayerJeffrey A Lieberman
Mar 8, 2003·Proceedings of the National Academy of Sciences of the United States of America·Daisuke YabeMichael S Brown
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Apr 2, 2003·The American Journal of Psychiatry·Gavin P ReynoldsXiaoBin Zhang
Jul 13, 2004·Schizophrenia Research·Jonathan M Meyer, Carol E Koro
Aug 3, 2004·The American Journal of Psychiatry·Stephen R MarderSteven Shon
Feb 25, 2005·Lipids·Manabu T NakamuraTakayuki Y Nara
May 14, 2005·The Journal of Clinical Psychiatry·Kaisa M SaariHannu J Koponen
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Nov 30, 2005·Psychiatric Genetics·Frank M TheisenJohannes Hebebrand
Apr 15, 2006·Science·Alan HerbertMichael F Christman
Jul 4, 2006·The American Journal of Psychiatry·J Steven LambertiMarci B Dietz
Jul 4, 2006·The American Journal of Psychiatry·Ya Mei BaiPesus Chou
Sep 20, 2006·Pharmacogenomics·Daniel J Müller, James L Kennedy
Feb 6, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Seunghyong RyuKyung Sue Hong
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Sangwon F KimSolomon H Snyder
May 2, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A J P SmithS E Humphries

❮ Previous
Next ❯

Citations

Aug 5, 2009·International Journal of Obesity : Journal of the International Association for the Study of Obesity·S W van den BergJ M A Boer
Mar 3, 2010·Molecular Psychiatry·D E AdkinsE J C G van den Oord
Jan 29, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Arun K TiwariDaniel J Müller
Aug 17, 2011·Pharmacogenomics·Arne J RisseladaToine C G Egberts
Nov 28, 2013·Pharmacogenomics·Amy C C Kao, Daniel J Müller
Jul 17, 2014·BioMed Research International·Fang-Hong LiuHai-Jun Wang
Sep 15, 2015·Expert Opinion on Drug Metabolism & Toxicology·Venuja SriretnakumarDaniel J Müller
Sep 8, 2010·Peptides·Xiao-Ying Dong, Sheng-Qiu Tang
Sep 14, 2010·Clinics in Laboratory Medicine·Peter P Zandi, Jennifer T Judy
Feb 18, 2010·The Psychiatric Clinics of North America·Peter P Zandi, Jennifer T Judy
Nov 26, 2009·Pharmacology & Therapeutics·Gavin P Reynolds, Shona L Kirk
Dec 27, 2008·Journal of Psychiatric Research·Stefan GebhardtFrank M Theisen
May 12, 2010·Journal of Clinical Pharmacy and Therapeutics·S GebhardtJ Hebebrand
Sep 10, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lin YangYifeng Xu
May 25, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ruili DangPing Xu
Feb 23, 2013·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Gavin P Reynolds
Mar 17, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Lin YangYifeng Xu
Jan 22, 2015·PloS One·Anne-Marie KaulfersLisa J Martin
Oct 22, 2013·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Fabiana Barzotti Kohlrausch
Nov 26, 2010·Journal of Clinical Psychopharmacology·Rocio Perez-IglesiasBenedicto Crespo-Facorro
Nov 26, 2011·Expert Review of Clinical Pharmacology·Maria J Arranz, Janet C Munro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.